Trevena's Phase II Pain Drug Bests Morphine
This article was originally published in Scrip
Trevena Inc.'s stock shot up this week on the news its post-operative pain drug met primary endpoints in a Phase IIb study – showing superiority over morphine.
You may also be interested in...
A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.